Axalbion Is A Clinical Stage Pharmaceutical Company Developing Trpm8 Agonists For The Treatment Of Chronic Cough And Dry Eyestwo Chroniccommon And Debilitating Disorderswith Unmet Needs And Multi Billion Dollar Markets Its Molecules Have A Rapid Onset Of Action And Offer Innovative Topical Treatment Opportunities By Normalizing Abnormal Cough And Lacrimation Reflexes Axalbion S S Strategy Is To Develop Its Lead Compound Ax 8 Up To Phase 2B To Show Clinical Proof Of Concept Across A Representative Patient Populationit Has Already Been Tested In A Phase 2A Trial With Patients Suffering From Refractory Chronic Cough Axalbion Benefits From Having Proof Of Concept Studiesclinical And Non Clinical Strong Safety And Toxicology Dataand The Support Of World S Leading Experts And Strategic Partners We Welcome Private Investors And Vc S To Contact Us Directly For Further Details Contact Axalbion Com
